Mahmoud Elesawy

MD passionate about science

[Kurt Prins @kurt_prins]

Ecstatic to share our latest work in @CircRes aimed at understanding RV dysfunction. Multi-omics analyses nominated underexplored pathways in severe RV dysfunction. https://t.co/C8I0wdjVrK. @Jenna_Mendelson @MadelynJBlake @MUSC_IM @PVRI @ATS_PC

[Diego Segura-Rodríguez @SeguraCardio]

📌Management of Type 2 Diabetes, 2026. A Consensus Report by the @AmDiabetesAssn and the @EASDnews

#PositionPaper #T2DM

[Journal of Clinical Investigation @jclinicalinvest]

We previously posted about the effects of SGLT2 inhibitors on ketone production related to the Research Letter (& Cover feature) by Abdualkader et al., “SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.”
✏️ Here, (https://t.co/Dc0EqVnOoP) Abdualrahman Mohammed Abdualkader @armak1983 & Rami Al Batran @AlbatranLab @UMontreal respond to a Letter to the Editor about assessing the clinical relevance of off-target effects observed at suprapharmacological concentrations of SGLT2 inhibitors.

[Nature Metabolism @NatMetabolism]

#Throwback
REVIEW |
R Mancina, @lucavalenti75, @stefano_romeo76

Human genetics of steatotic liver disease

https://t.co/pv5GbEsd5H

[Nature Metabolism @NatMetabolism]

Maternal obesity imprints methylation marks in oocytes to drive intergenerational metabolic dysfunction dlvr.​it/TVl8W9

[JACC Journals @JACCJournals]

What are the molecular pathways in the heart that are altered with #LVAD placement in bridge-to-transplant patients? Read about it in this month’s #JACCBTS to find out! https://t.co/66GvgT89Bq

[NEJM @NEJM]

In patients with #AFib and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation. Full SINGLE-AF trial results and Research Summary: https://t.co/rISG8pcl17

#ESCCongress

[NEJM @NEJM]

Original Article: Sodium Bicarbonate for Critically Ill Adults with Metabolic Acidosis and Shock (SODa-BIC trial) https://t.co/uTtuin6rig

Editorial: Sodium Bicarbonate in Critical Illness — A New Chapter for the Book https://t.co/pywzzcAkVV

#Nephrology #EmergencyMedicine

[Nature Metabolism @NatMetabolism]

Childhood proteomic signatures that predict adult cardiometabolic disease https://t.co/LflcXl51eX

[Enrico Ferro, MD @enricoferroMD]

Thrilled to share our latest study in @CircAHA: we ran one of the largest comparative safety analyses of #PFA vs radiofrequency #ablation for #AF, performed
@BIDMChealth (>1,500 #PVI/year). We found a significantly higher stroke risk with PFA. Read on👇

https://t.co/sFECm0SFaY

[Giuseppe Galati @GiuseppeGalati_]

🔥 📝 2026 ESC Guidelines for the management of heart failure:
Developed by the task force for the management of #HF of @escardio (ESC)

With the special contribution of the #HFA
Endorsed by the @EACTS

https://t.co/UERosIqhrG

☀️ Only #HFrEF & #HFpEF (No more #HFmrEF after 10 years of its definition)

✅ Better description of synergy between drugs and interventional procedures

🍀 Better characterization of #AvancedHF & indication of #LVAD & #HeartTransplantation

🖊️ Change of terminology “foundational therapy” ( no more GDMT), “Decompensated” (No more acute)

🫀 @HFUAcademy 🍀

https://t.co/0dFvFm9NeT

@EJHFEiC @HFA_President @gpontone1 @chiarabd @MicheleEmdin
@AmrAbdin10 @KTamirisaMD @DrRajivsankar @JBauersachsMD @robmentz @TomLuscher @AndrewJSauer
@DrMarthaGulati @FedericaFogacci @afgcicero @glimongelli @IacopoOlivotto @HanCardiomd @GMCRosano @SeguraCardio @ShelleyZieroth @chiarabd @iamritu @cristinagavina @FeliceGragnano @rahatheart1 @gpontone1 @stefanocarugo @AnastasiaSMihai @radcliffeCARDIO @GCFmeeting

[EJHF Editor-in-Chief @EJHFEiC]

Evaluation and management of HF patients with liver disease: #EJHF international expert position paper

https://t.co/g0Ws72tQgs

@SolovevaAnzhela @ARakisheva @HanCardiomd @AmrAbdin10 @GiuseppeGalati_

[Nature Metabolism @NatMetabolism]

A proteomic atlas of obesity and weight loss https://t.co/fyHKb6jc2V

[NEJM @NEJM]

Clinical Implications of Basic Research: Gene Editing, Peroxisomal Disorders, and Treatments for Rare Disease https://t.co/pGRqwdJQIh

#Genetics #Gastroenterology

[American College of Cardiology @ACCinTouch]

MERCURI-2: Starting dapagliflozin one day before elective cardiac surgery reduced the incidence of postoperative acute kidney injury during the first seven days after surgery.

Read the journal scan for more 👉 https://t.co/BQb02sTTDp #CardioX

[Journal of Gastroenterology and Hepatology @JGHofficial]

Can newer fibrosis scores improve screening in young adults with MASLD? 🎯📗 #TealJournal

Emerging indices outperform traditional scores for fibrosis—favoring lower referral thresholds in primary care and higher biopsy thresholds in tertiary care 🏥

🔗 https://t.co/Ey2FTHUJi0

[Cell Reports @CellReports]

Hyodeoxycholic acid suppresses hepatic steatosis in a PPARα-dependent manner via distinct GLP-1- and iNKT cell-mediated pathways https://t.co/PaVdhH4eK3

[JACC Journals @JACCJournals]

The liver leads. The heart follows 🫀

Read why metabolic dysfunction–associated steatotic liver disease risk may need to move into the cardiometabolic workflow NOW. https://t.co/DUIwrPwj0O

#JACC #CKMSyndrome #CKM #MASLD #cvMetabolic @FudimMarat

[JACC Journals @JACCJournals]

Secondary TR in pulmonary #hypertension is assoc w/ ⬆️symptoms, ⬆️congestion, & ⬆️mortality, beyond assoc RV dysfunction. Secondary TR could serve as a potential future therapeutic target. https://t.co/ahaqXuJ9nG

#JACCIMG #cvVHD #vhdTR @sarano_maurice @EleidMack @MayoClinicCV

[JACC Journals @JACCJournals]

Think #cvHCM is just a disease of sarcomeres? Think again. Learn about how it’s also a disease of metabolic and immune dysregulation and how targeting these axis through PPARg may offer a new therapeutic target in this month’s issue of #JACCBTS https://t.co/StCPvRGGRr